Watch: Dr Alasdair Bremner on Alusid’s growing global appeal
Alusid has signed its third international distribution agreement with one of Sweden’s largest tile suppliers Kakelspecialisten, a subsidiary of Saint Gobain, and raised £500,000. CEO Dr Alasdair Bremner discusses latest developments.
Read moreWatch: Dekiln CEO Dr Aled Roberts discusses £3m RAEng Green Future Fellowship award
Dr Aled Roberts, the chief executives officer of portfolio company Dekiln, discusses how the award will help the company scale up to industrial production.
Read moreDekiln to benefit from £3 million Royal Academy of Engineering fellowship award
The Royal Academy of Engineering has named Dekiln chief executive Dr Aled Roberts as an inaugural Green Future Fellow. The Fellowship brings with it £3 million of funding for Dekiln to use to scale up its kiln-free tile technology to industrial-scale production.
Read moreAlusid raises £500,000 in pre-IPO funding round
Alusid has raised £500,000 to support a potential IPO, to expand distribution networks and to develop existing and new technologies. The company has signed three international distribution agreements. Innovations include materials to make moulded products, such as basins and shower trays.
Read moreFull year results 2025: good technical and commercial progress in challenging times
Frontier IP and its portfolio companies made good technical and commercial progress in a year when difficult market conditions made exits difficult. The highlight was the strategic partners to open a new innovation hub in Cambridge.
Read moreAlusid signs deal with leading Swedish tile distributor
Alusid has signed its third international distribution deal with Kakelspecialisten, one of the Sweden’s largest tile distributors and a subsidiary of Saint-Gobain, a global leader in construction materials and services.
Read moreWatch: TVG CEO Jeremy Salt on BRSV vaccine success and next steps
The Vaccine Group has reported exceptional results for two vaccines to tackle a major cause of damaging bovine respiratory diseases, bovine respiratory syncytial virus.
Read moreOutstanding success for TVG in trials of vaccines to combat major livestock disease
The Vaccine Group has enjoyed outstanding success in trials of two vaccines to combat bovine respiratory syncytial virus (BRSV). The disease harms both beef and dairy cattle, and is estimated to cost farmers globally £5.6 billion a year.
Read moreWatch: Amprologix CSO Mat Upton on the first in a new class of antibiotics
Amprologix Chief Scientific Officer Mat Upton discusses the company’s recent fund raising raising, plans for a Series A round and the future of its novel antibiotics to tackle resistant diseases.
Read moreAmprologix raises £740,000 in pre-Series A funding round
Portfolio company raises money to accelerate development of antibiotics to combat antimicrobial resistant MRSA and other diseases. Its lead candidate epidermicin NI01 is the first in a new class of antibiotics.
Read moreWatch: Dekiln hits milestone with first commercial installation
Dekiln has completed the first commercial installation of Eralith, moved into new, larger premises to scale up, and won support from the Henry Royce Institute. Watch to learn more.
Read moreWatch: AquaInSilico CEO Jorge Santos on how Upwater could transform wastewater treatment
AquaInSilico co-founder and ceo Jorge Santos talks about the launch of Upwater, the company’s first commercial platform, and future scale up plans.
Read moreAquaInSilico launches first commercial services to reduce environmental impact of wastewater treatment
AquaInSilico has launched its first commercial services to help industry and government significantly reduce the environmental impact of their wastewater treatment plants.
Read moreWatch: Dekiln is scaling up says chief executive Dr Aled Roberts
Dekiln is to start scale up of its sustainable alternatives to ceramic tiles with plans to invest in an
Read more